Search Within

Robert T Heelan

  1. "Human Oncology and Pathogenesis Program"
Formats
  1. Meeting Abstract (5)
  2. Journal Article (4)
Groups
  1. Department of Medicine (9)
  2. Department of Pathology and Laboratory Medicine (9)
  3. GSK Faculty (9)
  4. Human Oncology and Pathogenesis Program (9)
  5. Solid Tumor Oncology Division (9)
  6. Thoracic Oncology (9)

More Groups

People
  1. Marc Ladanyi (9)
  2. Mark Kris (9)
  3. Maureen Zakowski (9)
  4. William Pao (8)
  5. Vincent Miller (7)
  6. Valerie Rusch (5)

More People

Years
  1. 2011 (1)
  2. 2009 (1)
  3. 2008 (1)
  4. 2007 (1)
  5. 2006 (1)
  6. 2005 (4)
Publications
  1. Journal of Clinical Oncology (4)
  2. Archives of Pathology & Laboratory Medicine (1)
  3. Clinical Cancer Research (1)
  4. Journal of Thoracic Oncology (1)
  5. Lung Cancer (1)
  6. PLos Medicine (1)
Publishers
  1. American Society of Clinical Oncology (4)
  2. American Association for Cancer Research (1)
  3. College of American Pathologists (1)
  4. Elsevier Inc. (1)
  5. Elsevier Ireland Ltd. (1)
  6. Public Library of Science (1)

Results (9)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Molecular characteristics predict clinical outcomes: Prospective trial correlating response to the EGFR tyrosine kinase inhibitor gefitinib with the presence of sensitizing mutations in the tyrosine binding domain of the EGFR gene
    Journal Article

    Rizvi, N. A.; Rusch, V.; Pao, W.; Chaft, J. E.; Ladanyi, M.; Miller, V. A.; Krug, L. M.; Azzoli, C. G.; Bains, M.; Downey, R.; more...
    Clinical Cancer Research (2011)

    Fulltext@MSK | Save
  • Morphologic features of adenocarcinoma of the lung predictive of response to the epidermal growth factor receptor kinase inhibitors erlotinib and gefitinib
    Journal Article

    Zakowski, M. F.; Hussain, S.; Pao, W.; Ladanyi, M.; Ginsberg, M. S.; Heelan, R.; Miller, V. A.; Rusch, V. W.; Kris, M. G.
    Archives of Pathology & Laboratory Medicine (2009)

    Fulltext@MSK | Save
  • Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib
    Journal Article

    Miller, V. A.; Riely, G. J.; Zakowski, M. F.; Li, A. R.; Patel, J. D.; Heelan, R. T.; Kris, M. G.; Sandler, A. B.; Carbone, D. P.; Tsao, A.; more...
    Journal of Clinical Oncology (2008)

    Fulltext@MSK | Save
  • Prospective trial of preoperative gefitinib to correlate response with EGFR exon 19 and 21 mutations and to select patients for adjuvant gefitinib
    Meeting Abstract

    Kris, M. G.; Pao, W.; Zakowski, Maureen F; Ladanyi, M.; Heelan, R. T.; Schwartz, L.; Zhao, B.; Venkatraman, E.; Rusch, V.; Rizvi, N. A.
    Journal of Thoracic Oncology (2007)

    Fulltext@MSK | Save
  • Prospective trial with preoperative gefitinib to correlate lung cancer response with EGFR exon 19 and 21 mutations and to select patients for adjuvant therapy
    Meeting Abstract

    Kris, M. G.; Pao, W.; Zakowski, M. F.; Ladanyi, M.; Heelan, R. T.; Schwartz, L.; Zhao, B.; Venkatraman, E.; Rusch, V.; Rizvi, N. A.
    Journal of Clinical Oncology (2006)

    Fulltext@MSK | Save
  • A prospective study to correlate EGFR mutations with gefitinib response in early stage NSCLC
    Meeting Abstract

    Rizvi, N.; Pao, W.; Miller, V.; Rusch, V.; Heelan, R.; Ladanyi, M.; Ginex, P.; Tyson, L.; Zakowski, M.; Kris, M.
    Lung Cancer (2005)

    Fulltext@MSK | Save
  • Clinical characteristics and natural history of patients with non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations treated with erlotinib or gefitinib
    Meeting Abstract

    Riely, G. J.; Miller, V. A.; Pao, W.; Zakowski, M.; Ladanyi, M.; Heelan, R. T.; Kris, M. G.
    Journal of Clinical Oncology (2005)

    Fulltext@MSK | Save
  • EGFR mutation, immumohistochemistry (IHC) and chromogenic in situ hybridization (CISH) as predictors of sensitivity to erlotinib and gefitinib in patients (pts) with NSCLC
    Meeting Abstract

    Miller, V. A.; Zakowski, M.; Riely, G. J.; Pao, W.; Hussain, S.; Ladanyi, M.; Heelan, R. T.; Kris, M. G.
    Journal of Clinical Oncology (2005)

    Fulltext@MSK | Save
  • KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib
    Journal Article

    Pao, W.; Wang, T. Y.; Riely, G. J.; Miller, V. A.; Pan, Q.; Ladanyi, M.; Zakowski, M. F.; Heelan, R. T.; Kris, M. G.; Varmus, H. E.
    PLos Medicine (2005)

    Fulltext@MSK | Save